文献速递免疫规划卫生政策与健康促进

日本儿童单价腮腺炎疫苗接种项目的成本效果分析

Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children.
PubMed 文献 · Vaccine · 2022-08-12

该研究用马尔可夫模型,从支付方与社会两个视角,比较1岁单剂、第二剂5岁接种的两剂程序与现状的成本效果。两种程序均减少治疗费用但不足以抵消接种成本,ICER均低于500万日元/QALY意愿支付阈值;概率敏感性分析显示两剂程序可接受性92.6%,为最优方案。

要点

  • 单剂与两剂程序ICER均低于500万日元(47,170美元)/QALY意愿支付阈值
  • 意愿支付阈值下可接受性:两剂程序92.6%、单剂程序0%、不接种7.4%
  • 腮腺炎病例中听力损失比例与疫苗有效性是改变ICER的关键变量

核心结论

  • 单剂与两剂常规接种程序从支付方和社会视角均具成本效果,两者中两剂程序更为有利。

研究设计与样本

  • 采用马尔可夫模型开展成本效果分析,计算1岁单剂程序与第二剂5岁接种的两剂程序相对现状的增量成本效果比(ICER),从支付方与社会两个视角分析;每剂接种成本假设为6140日元(58美元;1美元=106日元)。

主要发现

  • 两种程序均较现状降低疾病治疗费用,但费用下降不足以抵消接种成本。
  • 两种程序从任一视角的ICER均低于500万日元(47,170美元)/QALY的意愿支付阈值。
  • 概率敏感性分析以净货币效益表示:意愿支付阈值下可接受性两剂程序为92.6%、单剂程序为0%、现行不接种为7.4%。
  • 两剂程序在备选方案中最优。
  • 单因素敏感性分析显示,腮腺炎病例中腮腺炎相关听力损失的比例与疫苗有效性(VE)是改变ICER的关键变量。

关键数值与推荐

  • ICER阈值:低于500万日元(47,170美元)/QALY。
  • 每剂接种成本假设为6140日元(58美元;1美元=106日元)。
  • 意愿支付阈值下可接受性:两剂程序92.6%、单剂程序0%、不接种7.4%。

临床怎么用

  • 作者认为单剂与两剂常规接种程序均具成本效果,两者中两剂程序更为有利。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The most common preventative measure against mumps is vaccination with mumps vaccine. Over 122 countries have implemented mumps vaccine routine immunization programs, mostly via Measles-Mumps-Rubella (MMR) vaccine. In Japan, the unexpectedly high incidence of aseptic meningitis caused by mumps vaccine led to the discontinuation of the MMR national vaccination program in 1993, inadvertently resulting in the re-emergence of mumps. Plans of introducing monovalent mumps vaccine into routine vaccination schedule have become one of the emerging topics in health policy that has warranted the need in evaluating its value for money. METHODS: We conducted cost-effectiveness analyses with Markov model and calculated incremental cost-effectiveness ratios (ICERs) of two different vaccination programs (a single-dose program at one-year-old, a two-dose program with second dose uptakes at five) compared to status quo from both payers' and societal perspectives. Transition probabilities and utility weights in estimating quality-adjusted life-year (QALY), and disease treatment costs were either estimated or obtained from literature. Costs per vaccination were assumed at ¥6140 (US$58;1US$ = ¥106). RESULTS: Both programs reduce disease treatment costs compared to status quo, while the reduction cannot offset vaccination cost. ICER of either program is found to be under ¥5,000,000 (US$47,170)/QALY willingness-to-pay (WTP) threshold from either perspective. Results of probabilistic sensitivity analyses expressed by net monetary benefit indicated that at the WTP threshold, the acceptability is at 92.6% for two-dose vaccination program, 0% for single-dose vaccination program, and 7.4% for current no vaccination program. Two-dose program was optimal among the alternatives. One-way sensitivity analyses revealed that proportion of mumps-related hearing loss among mumps cases and vaccine effectiveness (VE) were key variables in changing the ICERs. CONCLUSION: Routine vaccination program of single- and two-dose programs were cost-effective from both payers' and societal perspectives. Between the two, the two-dose vaccination program was observed to be more favorable.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hoshi SL, Okubo R, Tabuchi K, et al. Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children. Vaccine. 2022. PMID: 35965241. doi:10.1016/j.vaccine.2022.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。